A Phase 1 Study to Evaluate the Relative Bioavailability of Octreotide Acetate Tablets(T25) Compared to MYCAPSSA® and The Food Effect on Pharmacokinetics Of Octreotide Acetate Tablets(T25) (clinicaltrials.gov) - Jun 24, 2026 - P1 | N=18 | Not yet recruiting | Sponsor: Triastek (Shanghai) Limited
New P1 trial • Acromegaly • Endocrine Disorders
|